Compare COHU & TYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | COHU | TYRA |
|---|---|---|
| Founded | 1947 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 2.0B |
| IPO Year | 1994 | 2021 |
| Metric | COHU | TYRA |
|---|---|---|
| Price | $44.21 | $25.54 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 11 |
| Target Price | $40.50 | ★ $47.50 |
| AVG Volume (30 Days) | ★ 842.7K | 522.2K |
| Earning Date | 04-30-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $452,956,000.00 | N/A |
| Revenue This Year | $14.38 | N/A |
| Revenue Next Year | $19.12 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 12.74 | N/A |
| 52 Week Low | $18.67 | $11.82 |
| 52 Week High | $74.60 | $40.65 |
| Indicator | COHU | TYRA |
|---|---|---|
| Relative Strength Index (RSI) | 36.97 | 40.05 |
| Support Level | $41.36 | $24.72 |
| Resistance Level | $58.18 | $27.02 |
| Average True Range (ATR) | 3.12 | 0.98 |
| MACD | -1.10 | 0.07 |
| Stochastic Oscillator | 4.13 | 44.02 |
Cohu Inc is a supplier of semiconductor test and inspection handlers, micro-electro-mechanical system (MEMS) test modules, test contactors, and thermal sub-systems used by semiconductor manufacturers and test subcontractors. The company's products include Semiconductor ATE (Automated Test Equipment), Semiconductor Handlers, Interface Products such as test contactors, probe heads, and probe pins, Spares and Kits, Bare Board PCB Test Systems, and services. It has one reportable segment, Semiconductor Test and Inspection Equipment (Semiconductor Test & Inspection). Geographically, the company generates maximum revenue from the Philippines, followed by Taiwan, China, Malaysia, the United States, Singapore, and the Rest of the world.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines for large opportunities in targeted oncology and genetically defined conditions, harnessing the power of Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are FGFR3, FGFR4/3, and FGFR1/2/3: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.